FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165594047> ?p ?o ?g. }

• W2165594047 endingPage "338" @default.
• W2165594047 startingPage "337" @default.
• W2165594047 abstract "Cefepime has recently drawn much attention, due mostly to a meta-analysis reported by Yahav et al. (3). They observed higher all-cause mortality for cefepime than for other beta-lactam antibiotics (risk ratio, 1.26; 95% confidence interval [CI], 1.08 to 1.49) and described neurotoxic adverse effects and inadequate in vivo antimicrobial efficacy as plausible reasons for increased mortality.Bhat et al. (1) observed increased mortality among cefepime-treated patients with bacteremia caused by gram-negative organisms when the cefepime MIC was ≥8 μg/ml (54.8%; 17 of 31 died) than when the MIC was <8 μg/ml (24.1%; 35 of 145 died). Based on pharmacodynamic and clinical grounds, they suggested that the current breakpoints (according to which organisms are considered susceptible if the MIC is ≤8 μg/ml by Clinical and Laboratory Standards Institute standards) for cefepime be lowered in countries where cefepime dosages of 1 to 2 g every 12 h is the licensed therapy for serious infections.However, we suppose that subgroup analysis excluding Pseudomonas aeruginosa and Acinetobacter spp. should reveal consistent results with statistical evidence to generalize their contention for other gram-negative organisms, because the MICs for P. aeruginosa and Acinetobacter spp. have been revealed to be much higher than those for other gram-negative organisms. Bhat et al. presented details on 204 bloodstream isolates from individual patients (the clinical outcomes for only 176 patients were analyzed because 21 patients were discharged within 28 days and 7 patients had two episodes of bacteremia), and P. aeruginosa and Acinetobacter spp. accounted for 79.4% (27 of 34) of the isolates for which the MICs were ≥8 μg/ml while they constituted only 15.9% (27 of 170) of those for which the MICs were <8 μg/ml. We could not identify the exact proportions of these two pathogens among isolates from nonsurvivors for which MICs were ≥8 μg/ml. However, Bhat et al. observed a high odds ratio (OR) for mortality among P. aeruginosa bacteremic patients through a subgroup analysis that compared outcomes associated with MICs of ≥8 μg/ml (mortality, 59.1%; 13 of 22 patients died) and those associated with MICs of ≤4 μg/ml (mortality, 20.8%; 5 of 24 patients died), and when a reconstituted population excluding P. aeruginosa was analyzed on the basis of MICs of ≥8 μg/ml versus MICs of ≤4 μg/ml, the analysis did not reveal statistical significance (4 of 9 patients [44.8%] with isolates for which MICs were ≥8 μg/ml died, and 30 of 121 [24.8%] with isolates for which MICs were <8 μg/ml died; OR = 2.4; 95% CI, 0.6 to 9.6). It seems quite reasonable to reconsider the current breakpoint MIC of cefepime (8 μg/ml) for P. aeruginosa. However, additional verification is required to resettle the cefepime MIC breakpoint for gram-negative pathogens other than P. aeruginosa and Acinetobacter spp. We believe that this verification may be accomplished through a subgroup analysis excluding P. aeruginosa and Acinetobacter spp. and providing statistical evidence.In 2006, the probability of target attainment (PTA) for the conventional dose of cefepime (2 g every 12 h) against common intensive care unit (ICU) pathogens in ICU patients was estimated (2). According to the results of the study, higher doses of cefepime (>4 g/day) are required to achieve the required PTA expectation value for P. aeruginosa, and even a higher dose (6 g/day) failed to achieve the bactericidal target for Acinetobacter baumannii, unlike that for other pathogens.Like various MIC distributions, we suppose that MIC breakpoint resettlement requires verifications for different pathogens." @default.
• W2165594047 created "2016-06-24" @default.
• W2165594047 creator A5039310818 @default.
• W2165594047 creator A5050102895 @default.
• W2165594047 date "2009-01-01" @default.
• W2165594047 modified "2023-09-23" @default.
• W2165594047 title "Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria" @default.
• W2165594047 cites W1977259750 @default.
• W2165594047 cites W2098357010 @default.
• W2165594047 cites W2106729847 @default.
• W2165594047 cites W2126528279 @default.
• W2165594047 cites W2127429285 @default.
• W2165594047 cites W2132112261 @default.
• W2165594047 doi "https://doi.org/10.1128/aac.00106-08" @default.
• W2165594047 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2612191" @default.
• W2165594047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19109242" @default.
• W2165594047 hasPublicationYear "2009" @default.
• W2165594047 type Work @default.
• W2165594047 sameAs 2165594047 @default.
• W2165594047 citedByCount "5" @default.
• W2165594047 countsByYear W21655940472014 @default.
• W2165594047 countsByYear W21655940472015 @default.
• W2165594047 crossrefType "journal-article" @default.
• W2165594047 hasAuthorship W2165594047A5039310818 @default.
• W2165594047 hasAuthorship W2165594047A5050102895 @default.
• W2165594047 hasBestOaLocation W21655940472 @default.
• W2165594047 hasConcept C104317684 @default.
• W2165594047 hasConcept C138626823 @default.
• W2165594047 hasConcept C161369605 @default.
• W2165594047 hasConcept C206936463 @default.
• W2165594047 hasConcept C2776051709 @default.
• W2165594047 hasConcept C2777050379 @default.
• W2165594047 hasConcept C2779518903 @default.
• W2165594047 hasConcept C2779631663 @default.
• W2165594047 hasConcept C523546767 @default.
• W2165594047 hasConcept C54355233 @default.
• W2165594047 hasConcept C547475151 @default.
• W2165594047 hasConcept C86803240 @default.
• W2165594047 hasConcept C89423630 @default.
• W2165594047 hasConcept C94665300 @default.
• W2165594047 hasConceptScore W2165594047C104317684 @default.
• W2165594047 hasConceptScore W2165594047C138626823 @default.
• W2165594047 hasConceptScore W2165594047C161369605 @default.
• W2165594047 hasConceptScore W2165594047C206936463 @default.
• W2165594047 hasConceptScore W2165594047C2776051709 @default.
• W2165594047 hasConceptScore W2165594047C2777050379 @default.
• W2165594047 hasConceptScore W2165594047C2779518903 @default.
• W2165594047 hasConceptScore W2165594047C2779631663 @default.
• W2165594047 hasConceptScore W2165594047C523546767 @default.
• W2165594047 hasConceptScore W2165594047C54355233 @default.
• W2165594047 hasConceptScore W2165594047C547475151 @default.
• W2165594047 hasConceptScore W2165594047C86803240 @default.
• W2165594047 hasConceptScore W2165594047C89423630 @default.
• W2165594047 hasConceptScore W2165594047C94665300 @default.
• W2165594047 hasIssue "1" @default.
• W2165594047 hasLocation W21655940471 @default.
• W2165594047 hasLocation W21655940472 @default.
• W2165594047 hasLocation W21655940473 @default.
• W2165594047 hasLocation W21655940474 @default.
• W2165594047 hasOpenAccess W2165594047 @default.
• W2165594047 hasPrimaryLocation W21655940471 @default.
• W2165594047 hasRelatedWork W1605926837 @default.
• W2165594047 hasRelatedWork W1991977026 @default.
• W2165594047 hasRelatedWork W2020437228 @default.
• W2165594047 hasRelatedWork W2125483903 @default.
• W2165594047 hasRelatedWork W2165594047 @default.
• W2165594047 hasRelatedWork W2897465956 @default.
• W2165594047 hasRelatedWork W2996042603 @default.
• W2165594047 hasRelatedWork W3084212313 @default.
• W2165594047 hasRelatedWork W3183930985 @default.
• W2165594047 hasRelatedWork W56454504 @default.
• W2165594047 hasVolume "53" @default.
• W2165594047 isParatext "false" @default.
• W2165594047 isRetracted "false" @default.
• W2165594047 magId "2165594047" @default.
• W2165594047 workType "article" @default.